Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

Impact · against what's priced in

HROW presents a valuation gap where flagship drugs Vevye and Iheezo may be undervalued, but a persistent risk premium remains due to a history of earnings misses. The upside is contingent on the company transitioning from inconsistent execution to predictable delivery.

HROW+0.30

No priced-in read yet

In context

DCF analysis suggests the current price is 40% below what is justified by Vevye and Iheezo alone, though this potential is offset by a history of missing consensus estimates 5 times in the last 8 quarters.

Read from the article alone

• biotech▲<1%
• healthcare
• valuation
• pharmaceuticals
• fundamental analysis
• HROW
• dcf
• drug pipeline

Top 1 mover · tap to explore